Additive beneficial effects of valsartan combined with rosuvastatin in the treatment of hypercholesterolemic hypertensive patients

• Published in: Korean circulation journal 2015, 45(3), , pp.225-233
• Main Authors: Jang, Ji-Yong, Lee, Sang-Hak, Kim, Byung Soo, Seo, Hong Seog, Kim, Woo-Shik, Ahn, Youngkeun, Lee, Nae-Hee, Koh, Kwang Kon, Kang, Tae-Soo, Jo, Sang-Ho, Hong, Bum-Kee, Bae, Jang-Ho, Yang, Hyoung-Mo, Cha, Kwang Soo, Kim, Bum Soo, Kwak, Choong Hwan, Cho, Deok-Kyu, Kim, Ung, Zo, Joo-Hee, Kang, Duk-Hyun, Pyun, Wook Bum, Chun, Kook Jin, Namgung, June, Cha, Tae-Joon, Juhn, Jae-Hyeon, Jung, YeiLi, Jang, Yangsoo
• Format: Article
• Language: English
• Subjects: Original; 내과학
• ISSN: 1738-5520; 1738-5555
• DOI: 10.4070/kcj.2015.45.3.225

We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. Patients who met inclusion criteria were randomized to receive 1 of the following 2-month drug regimens: valsartan 160 mg plus rosuvastatin 20 mg, valsartan 160 mg plus placebo, or rosuvastatin 20 mg plus placebo. The primary efficacy variables were change in sitting diastolic blood pressure (sitDBP) and sitting systolic blood pressure (sitSBP), and percentage change in low-density lipoprotein-cholesterol (LDL-C) in the combination, valsartan, and rosuvastatin groups. Adverse events (AEs) during the study were analyzed. A total of 354 patients were screened and 123 of them were finally randomized. Changes of sitDBP by least squares mean (LSM) were -11.1, -7.2, and -3.6 mm Hg, respectively, and was greater in the combination, as compared to both valsartan (p=0.02) and rosuvastatin (p